Vigil Neuroscience (VIGL) to Release Quarterly Earnings on Tuesday

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) is expected to release its earnings data before the market opens on Tuesday, March 25th. Analysts expect Vigil Neuroscience to post earnings of ($0.51) per share for the quarter.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.08). On average, analysts expect Vigil Neuroscience to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Vigil Neuroscience Trading Up 2.4 %

VIGL stock traded up $0.05 during midday trading on Friday, reaching $1.89. The stock had a trading volume of 102,464 shares, compared to its average volume of 469,099. Vigil Neuroscience has a 52-week low of $1.49 and a 52-week high of $6.06. The company's fifty day simple moving average is $2.35 and its 200 day simple moving average is $2.75. The company has a market cap of $77.06 million, a price-to-earnings ratio of -0.92 and a beta of 1.82.

Wall Street Analyst Weigh In

VIGL has been the topic of several research reports. William Blair began coverage on shares of Vigil Neuroscience in a research note on Wednesday, December 4th. They issued an "outperform" rating on the stock. JMP Securities restated a "market outperform" rating and set a $22.00 target price on shares of Vigil Neuroscience in a report on Tuesday, November 26th. Guggenheim reaffirmed a "buy" rating on shares of Vigil Neuroscience in a report on Friday, January 24th. Wedbush reduced their price objective on Vigil Neuroscience from $24.00 to $13.00 and set an "outperform" rating on the stock in a research report on Friday, March 14th. Finally, HC Wainwright dropped their price objective on shares of Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating for the company in a report on Friday, March 14th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Vigil Neuroscience currently has an average rating of "Buy" and a consensus price target of $16.25.

Remove Ads

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.